Loading...
Targeted replacement of full-length CFTR in human airway stem cells by CRISPR-Cas9 for pan-mutation correction in the endogenous locus
Vaidyanathan, Sriram ; Baik, Ron ; ; Bravo, Dawn T. ; Suarez, Carlos J. ; Abazari, Shayda M. ; Salahudeen, Ameen A. ; Dudek, Amanda M. ; Teran, Christopher A. ; David, Timothy H. ... show 10 more
Vaidyanathan, Sriram
Baik, Ron
Bravo, Dawn T.
Suarez, Carlos J.
Abazari, Shayda M.
Salahudeen, Ameen A.
Dudek, Amanda M.
Teran, Christopher A.
David, Timothy H.
Citations
Altmetric:
Genre
Journal article
Date
2022-01-05
Advisor
Committee member
Department
Cancer and Cellular Biology
Permanent link to this record
Collections
Research Projects
Organizational Units
Journal Issue
DOI
https://doi.org/10.1016/j.ymthe.2021.03.023
Abstract
Cystic fibrosis (CF) is a monogenic disease caused by impaired production and/or function of the CF transmembrane conductance regulator (CFTR) protein. Although we have previously shown correction of the most common pathogenic mutation, there are many other pathogenic mutations throughout the CF gene. An autologous airway stem cell therapy in which the CFTR cDNA is precisely inserted into the CFTR locus may enable the development of a durable cure for almost all CF patients, irrespective of the causal mutation. Here, we use CRISPR-Cas9 and two adeno-associated viruses (AAVs) carrying the two halves of the CFTR cDNA to sequentially insert the full CFTR cDNA along with a truncated CD19 (tCD19) enrichment tag in upper airway basal stem cells (UABCs) and human bronchial epithelial cells (HBECs). The modified cells were enriched to obtain 60%–80% tCD19+ UABCs and HBECs from 11 different CF donors with a variety of mutations. Differentiated epithelial monolayers cultured at air-liquid interface showed restored CFTR function that was >70% of the CFTR function in non-CF controls. Thus, our study enables the development of a therapy for almost all CF patients, including patients who cannot be treated using recently approved modulator therapies.
Description
Citation
Vaidyanathan S, Baik R, Chen L, Bravo DT, Suarez CJ, Abazari SM, et al. Targeted replacement of full-length CFTR in human airway stem cells by CRISPR-Cas9 for pan-mutation correction in the endogenous locus. Mol. Ther. 2021 Mar 29;30(1):223-237. doi:10.1016/j.ymthe.2021.03.023.
Citation to related work
Cell Press
Has part
Molecular Therapy, Vol. 30, Iss. 1
ADA compliance
For Americans with Disabilities Act (ADA) accommodation, including help with reading this content, please contact scholarshare@temple.edu